Greenwood Capital Associates LLC Purchases 1,648 Shares of Bristol-Myers Squibb (NYSE:BMY)

Greenwood Capital Associates LLC raised its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.1% during the first quarter, HoldingsChannel reports. The fund owned 34,047 shares of the biopharmaceutical company’s stock after acquiring an additional 1,648 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Bristol-Myers Squibb were worth $2,077,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Wealthspire Advisors LLC increased its position in Bristol-Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock valued at $1,622,000 after acquiring an additional 170 shares during the last quarter. Bedel Financial Consulting Inc. grew its holdings in shares of Bristol-Myers Squibb by 3.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock worth $340,000 after purchasing an additional 175 shares during the last quarter. King Wealth Management Group grew its holdings in shares of Bristol-Myers Squibb by 2.6% in the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 182 shares during the last quarter. Signet Investment Advisory Group Inc. grew its holdings in shares of Bristol-Myers Squibb by 2.3% in the fourth quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company’s stock worth $467,000 after purchasing an additional 189 shares during the last quarter. Finally, Thoroughbred Financial Services LLC grew its holdings in shares of Bristol-Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company’s stock worth $1,004,000 after purchasing an additional 190 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Stock Up 0.3%

BMY stock opened at $50.13 on Thursday. The firm has a 50 day moving average of $48.87 and a 200 day moving average of $54.88. The stock has a market capitalization of $102.01 billion, a PE ratio of -11.34, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period last year, the business earned ($4.40) EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Jefferies Financial Group cut their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.